You haven't searched anything yet.
ABOUT THE FLOCK
As a member of the Market Access team (at bluebird, it’s Access, Value, and Evidence Strategy, “AVES”), you will be working alongside some of the most committed, creative, and experienced individuals in the cell and gene therapy industry to break new ground so that patients can access our FDA-approved gene therapies—patients who often have no therapeutic alternatives to battle progressive, debilitating, and life-shortening diseases. We are passionate about the science behind our gene therapies and the tremendous value we believe these one-time administered, potentially curative therapies bring to patients, their families, the healthcare system, and society overall. Everyone on our team has external-facing responsibilities, so we aim to be integrated and data- and evidence-driven to capitalize on the dynamic flow of information and insights across stakeholders (always being sure to maintain the highest standards of compliance). Join us if you too work best in a fast-paced and highly collaborative environment!
HOW YOU’LL FLY
You'll help to bring more patients their bluebird days by:
WHAT YOU’LL BRING
You’re the bird we’re looking for if you have:
Compensation & Benefits
We offer a total compensation and rewards package that ranks among the best in our industry. Base pay is one part of our total compensation package and is determined within a range. This provides the opportunity to progress as you grow and develop within a role. The anticipated annualized salary range for this role is $200,000 - $260,000. Your base pay will be determined based on several factors including market data, demonstrated skills, relevant education or training, experience, qualifications, internal equity, and travel requirements. Our overall package also includes eligibility for stock, incentive bonuses, and benefit programs, a flexible time off program, as well as paid holidays, bluebird days, and a holiday shutdown in December.
Full Time
Durable Manufacturing
$101k-138k (estimate)
03/21/2024
06/29/2024
bluebirdbio.com
CAMBRIDGE, MA
1,000 - 3,000
1993
Public
NICK LESCHLY
$200M - $500M
Durable Manufacturing
bluebird focuses on developing transformative gene therapies for severe genetic diseases and cancer.